Novo Nordisk A/S (NVO) Stock

About Novo Nordisk A/S

Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S is led by CEO Maziar Mike Doustdar, employs 77,406 people, headquartered in Bagsvaerd, DK, publicly traded since 1981.

Novo Nordisk A/S (NVO) stock trades at $51.58 with a market capitalization of $229.21B. The stock is valued at a price-to-earnings (P/E) ratio of 1.94, price-to-book of 1.02, price-to-sales of 4.05. Over the past 52 weeks the stock has ranged between $35.12 and $71.80, and currently trades 28.2% below its 52-week high. It pays a dividend yielding 3.91%.

On profitability, Novo Nordisk A/S generates a return on equity (ROE) of 52.79% — well above the market average, a sign of a high-quality business, return on capital employed of 65.79%, an operating margin of 41.30%, a net profit margin of 37.20%.

In its most recent fiscal year, Novo Nordisk A/S reported annual revenue of $309.1B, net profit of $102.4B, revenue has compounded at 19.5% a year over the last five years, profit at 19.4% a year.

The balance sheet shows a debt-to-equity ratio of 0.72, a current ratio of 0.80, total assets of $542.9B, $26.5B in cash and equivalents.

NVO has an average daily trading volume of 12,814,806 shares, a beta of 0.35 (less volatile than the overall market).

Official website: www.novonordisk.com